Skip to main content

Local Control Options for Metastatic Disease in Sarcoma

In brief

Selected sarcoma patients have 20% to 58% five-year survival after lung metastasectomy

In oligometastatic soft tissue sarcoma, reported five-year survival after lung metastasectomy ranges from 20% to 58%; complete tumor removal, fewer metastases, and a longer disease-free interval are linked to better outcomes. Stereotactic radiotherapy and thermal ablation are other local options, but evidence is mostly retrospective, so their comparative benefits and the best candidates remain uncertain.

Journal
Current oncology reports (Q1)
Published
11 November 2026
Study design
Systematic review of cohort studies
Evidence level
Level 2, Moderate (CEBM 2a)
Authors
G F Foppele, H Gelderblom, M A J van de Sande, Q R J G Tummers, K F M Hergaarden, R L Haas, et al.
PMID
43013146
DOI
10.1007/s11912-026-01865-5

Why clinicians should know about it

  • Picked for Surgical Oncology (top studies of the week, 15 November 2026): Local control for sarcoma metastases, surgery options

Abstract

PURPOSE OF REVIEW: To review the current evidence on local treatment strategies for oligometastatic soft tissue sarcoma at pulmonary and extrapulmonary sites, and evaluate their impact on oncological outcomes. RECENT FINDINGS: Pulmonary metastasectomy remains the most established local treatment, with 5-year survival rates of 20-58%. Complete (R0) resection, a longer disease-free interval, and fewer metastases are associated with improved outcomes. Stereotactic radiotherapy achieves high local control rates with low toxicity, and a recent systematic review reported survival outcomes comparable to surgery. Image-guided thermal ablation also achieves high local control rates for lung metastases of 1 cm or smaller and offers a minimally invasive option for extrapulmonary metastases. For all modalities, current data are derived predominantly from retrospective studies, and direct comparisons are lacking. Local treatment offers promising outcomes for carefully selected patients with oligometastatic soft tissue sarcoma. Surgery, stereotactic radiotherapy, and thermal ablation should be considered complementary options, selected within a multidisciplinary tumor board according to lesion size, number, and location. Prospective studies are needed to define optimal patient selection and determine the comparative effectiveness of these modalities.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.